Blu Label Unlimited Group (BLU) Trading update summary
Event summary combining transcript, slides, and related documents.
Trading update summary
13 Aug, 2026Financial performance overview
Basic earnings per share for the six months ended 30 November 2025 are expected to decrease by more than 20% compared to the prior year period.
Excluding Cell C and CEC, revenue was R5 billion, gross income R1.353 billion, EBITDA R535 million, and net profit after tax R389 million.
Core headline earnings per share are expected to be between 40.64 and 42.53 cents, a decrease of 10% to 14% from the prior period.
Headline earnings per share are expected to decrease by 14% to 18%, to a range of 37.68 to 39.52 cents.
Corporate actions and restructuring
TPC acquired control of Cell C in September 2025, then disposed of a 50.45% shareholding and sold CEC to Cell C at the end of November 2025.
Blu Label now holds a 49.47% interest in Cell C, which is equity accounted as an associate from November 2025.
Cell C's results are consolidated for three months and equity accounted for three months in the reporting period.
Significant items impacting results
A net loss of R5.2 billion related to the investment in Cell C is included in earnings, mainly from a R6 billion loss on disposal, partially offset by an R841 million gain on remeasurement.
These losses are added back for headline earnings calculations.
Latest events from Blu Label Unlimited Group
- AGM approved key resolutions, addressed diversity, ESG, and Cell C governance, with most motions passed.BLU
AGM 2024 - Significant declines in earnings expected due to Cell C restructuring and listing impacts.BLU
Trading update - Normalized revenue ZAR 9.4bn, EBITDA ZAR 923m, core headline earnings ZAR 681m, dividend and buyback.BLU
H2 2026 - Earnings per share are expected to rise over 100%, but underlying earnings fell when excluding Cell C effects.BLU
Trading update - Earnings per share are expected to rise by over 20% for the year ended 31 May 2025.BLU
Trading update - Gross revenue up 16% to ZAR 89.3bn, but core HEPS down 34% amid challenging conditions.BLU
H2 2024 - Gross revenue up 8% to R47.4bn, margins improved, but EBITDA fell on higher finance costs.BLU
H1 2025 - Profit and margin growth accelerated, led by digital innovation and Cell C's operational turnaround.BLU
H2 2025 - Cell C restructuring and 11% revenue growth enabled dividend resumption and strong cash flow.BLU
H1 2026